| Literature DB >> 27007495 |
Wan Yee Lau1, Yee Leong Teoh2, Khin Maung Win3, Rheun-Chuan Lee4, Vanessa H de Villa5,6, Yun Hwan Joseph Kim7, Po-Chin Liang8, Ramon S Santos-Ocampo9, Richard Hoau Gong Lo10, Kieron Boon Leng Lim11, David Wai Meng Tai12, David Chee Eng Ng13, Farah Gillan Irani10, Apoorva Gogna10, Pierce Kah-Hoe Chow14,15.
Abstract
An expert panel met to review the evidence for selective internal radiation therapy (SIRT) using yttrium-90 microspheres in hepatocellular carcinoma and metastases from colorectal cancer and neuroendocrine tumors. There is now convincing evidence for the safety and efficacy of SIRT in these situations albeit mostly from retrospective cohort studies. There are a number of ongoing prospective randomized controlled clinical trials investigating the role of SIRT in liver tumors; however, data from these trials are still several years away (although the SIRFLOX study has been recently published). In this evolving environment, published evidence and the authors' experience were used to summarize the current and potential role of SIRT in the management of hepatocellular carcinoma of intermediate or advanced stage and in liver-dominant metastatic colorectal cancer and metastatic neuroendocrine tumors.Entities:
Keywords: liver cancer; selective internal radiation; transarterial chemoembolization; yttrium 90 microspheres
Mesh：
Substances：
Year: 2016 PMID： 27007495 DOI： 10.2217/fon-2016-0035
Source DB: PubMed Journal: Future Oncol ISSN： 1479-6694 Impact factor: 3.404